Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis
Por:
Zozaya González N, Abdalla F, Alfonso Zamora S, Balea Filgueiras J, Carrascosa Carrillo JM, Delgado Sánchez O, Dolz Sinisterra F, García-Ruiz A, Herranz Pinto P, Manfredi A, Martínez Olmos J, Morales de Los Ríos Luna P, Puig L, Ros S and Hidalgo Á
Publicada:
18 ago 2022
Ahead of Print:
1 abr 2022
Resumen:
Background Multi-criteria decision analysis (MCDA) was proposed to surmount arbitrary clinical decisions in the field of biological therapies for psoriatic patients. At the same time, MCDA may further highlight the potential of bimekizumab for the treatment of moderate-to-severe psoriasis, compared to placebo, adalimumab, ustekinumab, secukinumab, and even ixekizumab and risankizumab. Research design and methods The EVIDEM framework was adapted to reflect relevant criteria for the assessment. Estimated values were obtained by means of an additive linear model combining weights and scores assigned by a multidisciplinary committee of 12 experts. Consistency and replicability were evaluated through an alternative weighting method and a re-test. Results Bimekizumab was assessed by the committee as an intervention with a positive value contribution for the treatment of moderate-to-severe psoriasis in comparison to any of the alternatives. The drug provides a substantial therapeutical benefits and improves the health results reported by the patients, as it combines a higher level of clearance, rapidity, and persistence with a similar safety and tolerability profile. Conclusions Under a methodology with increasing use in the health field, bimekizumab was evaluated as a drug with a high added value for the treatment of moderate-to-severe psoriasis when compared to six different alternatives.
Filiaciones:
Zozaya González N:
Department of Health Economics, Weber, Madrid, Spain
Department of Quantitative Methods in Economics and Management, University Las Palmas de Gran Canaria. Las Palmas, Spain
Abdalla F:
Department of Health Economics, Weber, Madrid, Spain
Alfonso Zamora S:
Department of Management, Psoriasis and Psoriatic Arthritis Patient and Family Association (Acción Psoriasis), Barcelona, Spain
Balea Filgueiras J:
Department of Pharmacy, Ferrol University Hospital Complex, La Coruña, Spain
Carrascosa Carrillo JM:
Department of Dermatology, Germans Trias i Pujol University Hospital, Badalona, Spain
Delgado Sánchez O:
Department of Management, Spanish Society of Hospital Pharmacy (SEFH). Department of Pharmacy, Son Espases University Hospital, Illes Balears, Spain
:
Department of Management, Doctor Peset University Hospital, Valencia, Spain
García-Ruiz A:
Health Economics and Rational Use of Medicines. Department of Pharmacology and Clinical Therapeutics, Biomedical Research Institute of Malaga (IBIMA). University of Malaga, Malaga, Spain
Herranz Pinto P:
Department of Dermatology, La Paz University Hospital, Madrid, Spain
Manfredi A:
Department of Management, Psoriasis and Psoriatic Arthritis Patient and Family Association (Acción Psoriasis), Barcelona, Spain
Martínez Olmos J:
Andalusian Public Health School (EASP), Granada, Spain
Morales de Los Ríos Luna P:
Department of Nursing, Gregorio Marañón University Hospital, Madrid, Spain
Puig L:
Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
Ros S:
Department of Dermatology, Rheumatology and Cardiac Transplantation, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Hidalgo Á:
Weber Foundation, Madrid, Spain
Department of Economic Analysis and Finances, University of Castilla-La Mancha. Toledo, Spain
hybrid
|